PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

Cashing in on the exuberance around Karuna Therapeutics and its potential blockbuster CNS drug, PureTech has sold a chunk of the biotech’s shares to Goldman Sachs for $200 million.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

Updated: FDA signals likely full approval for Eisai's new Alzheimer's drug ahead of Friday's adcomm

FDA commissioner says drug prices are too high, calls for better evidence generation

Tiny biotech takes on mRNA vaccine juggernauts in federal court in patent infringement cases

Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Amber Tong

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Up­dat­ed: FDA sig­nals like­ly full ap­proval for Ei­sai's new Alzheimer's drug ahead of Fri­day's ad­comm

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

Tiny biotech takes on mR­NA vac­cine jug­ger­nauts in fed­er­al court in patent in­fringe­ment cas­es

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

Updated: FDA signals likely full approval for Eisai's new Alzheimer's drug ahead of Friday's adcomm

FDA commissioner says drug prices are too high, calls for better evidence generation

Tiny biotech takes on mRNA vaccine juggernauts in federal court in patent infringement cases

Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape